RESUMEN
INTRODUCTION: Different alcoholic beverages exert different effects on inflammation and oxidative stress but these results are controversial and scanty in some aspects. We analyze the effect of different alcoholic beverages after a fat-enriched diet on lipid profile, inflammatory factors and oxidative stress in healthy people in a controlled environment. METHODS: We have performed a cross-over design in five different weeks. Sixteen healthy volunteers have received the same oral fat-enriched diet (1486kcal/m(2)) and a daily total amount of 16g/m(2) of alcohol, of different beverages (red wine, vodka, brandy or rum) and equivalent caloric intakes as sugar with water in the control group. We have measured the levels of serum lipids, high sensitivity C-reactive protein (hsCRP), tumor necrosis factor α (TNFα), interleukin 6 (IL-6), soluble phospholipase A2 (sPLA2), lipid peroxidation (LPO) and total antioxidant capacity (TAC). RESULTS: Red wine intake was associated with decreased of mean concentrations of hsCRP, TNFα and IL-6 induced by fat-enriched diet (p<0.05); nevertheless, sPLA2 concentrations were not significantly modified. After a fat-enriched diet added with red wine, TAC increased as compared to the same diet supplemented with rum, brandy, vodka or the control (water with sugar) (p<0.05). CONCLUSIONS: Moderate red wine intake, but not other alcoholic beverages, decreased pro-inflammatory factors and increased total antioxidant capacity despite a fat-enriched diet intake in healthy young volunteers.
RESUMEN
Niemann-Pick disease (NPD) types A and B are autosomal, recessively inherited, lysosomal storage disorders caused by deficient activity of acid sphingomyelinase (E.C. 3.1.4.12) because of mutations in the sphingomyelin phosphodiesterase-1 (SMPD1) gene. Here, we present the molecular analysis and clinical characteristics of 15 NPD type A and B patients. Sequencing the SMDP1 gene revealed eight previously described mutations and seven novel mutations including four missense [c.682T>C (p.Cys228Arg), c.1159T>C (p.Cys387Arg), c.1474G>A (p.Gly492Ser), and c.1795C>T (p.Leu599Phe)], one frameshift [c.169delG (p.Ala57Leufs*20)] and two splicing (c.316+1G>T and c.1341delG). The most frequent mutations were p.Arg610del (21%) and p.Gly247Ser (12%). Two patients homozygous for p.Arg610del and initially classified as phenotype B showed different clinical manifestations. Patients homozygous for p.Leu599Phe had phenotype B, and those homozygous for c.1341delG or c.316+1G>T presented phenotype A. The present results provide new insight into genotype/phenotype correlations in NPD and emphasize the difficulty of classifying patients into types A and B, supporting the idea of a continuum between these two classic phenotypes.
Asunto(s)
Mutación , Enfermedades de Niemann-Pick/diagnóstico , Enfermedades de Niemann-Pick/genética , Esfingomielina Fosfodiesterasa/genética , Sustitución de Aminoácidos , Orden Génico , Estudios de Asociación Genética , Genotipo , Humanos , FenotipoRESUMEN
We present the Spanish adaptation made by the CEIPC of the European Guidelines on Cardiovascular Disease Prevention (CVD) in Clinical Practice 2008. This guide recommends the SCORE model for risk evaluation. The aim is to prevent premature mortality and morbidity due to CVD through the management of its related risk factors in clinical practice. The guide focuses on primary prevention and emphasizes the role of the nurses and primary care medical doctors in promoting a healthy life style, based on increasing physical activity, change dietary habits, and non smoking. The therapeutic goal is to achieve a Blood Pressure < 140/90 mmHg, but among patients with diabetes, chronic kidney disease, or definite CVD, the objective is <130/80 mmHg. Serum cholesterol should be < 200 mg/dl and cLDL<130 mg/dl, although among patients with CVD or diabetes, the objective is <100 mg/dl (80 mg/dl if feasible in very high-risk patients). Patients with type 2 diabetes and those with metabolic syndrome must lose weight and increase their physical activity, and drugs must be administered whenever applicable, to reach body mass index (BMI) guided and waist circumference objectives. In diabetic type 2 patients, the objective is glycated haemoglobin <7%. Allowing people to know the guides and developing implementation programs, identifying barriers and seeking solutions for them, are priorities for the CEIPC in order to transfer the recommendations established into the daily clinical practice.
Asunto(s)
Enfermedades Cardiovasculares/prevención & control , Medicina Clínica/normas , Factores de Edad , Biomarcadores , Presión Sanguínea , Índice de Masa Corporal , Enfermedades Cardiovasculares/mortalidad , Enfermedades Cardiovasculares/fisiopatología , Enfermedades Cardiovasculares/terapia , Colesterol/sangre , Ensayos Clínicos como Asunto , Diabetes Mellitus Tipo 2/prevención & control , Humanos , Estilo de Vida , Inhibidores de Agregación Plaquetaria/uso terapéutico , Pautas de la Práctica en Medicina , Factores de Riesgo , EspañaRESUMEN
Presentamos la adaptación española realizada por el CEIPC de la Guía Europea de Prevención de las Enfermedades Cardiovasculares (ECV) 2008. Esta guía recomienda el modelo SCORE de bajo riesgo para la valoración del riesgo cardiovascular. El objetivo es prevenir la mortalidad y morbilidad debidas a las ECV mediante el manejo de sus factores de riesgo en la práctica clínica. La guía hace énfasis en la prevención primaria y en el papel del médico y la enfermería de atención primaria en la promoción de un estilo de vida saludable, basado en el incremento de los niveles de actividad física, la adopción de una alimentación saludable y, en los fumadores, el abandono del tabaco. La meta terapéutica para la presión arterial es en general <140/90 mmHg; pero en pacientes con diabetes, enfermedad renal crónica o ECV el objetivo es 130/80 mmHg. El colesterol debe mantenerse por debajo de 200 mg/dl (cLDL<130 mg/dl); en los pacientes con ECV o diabetes el objetivo es cLDL<100 mg/dl (80 mg/dl si factible en sujetos de muy alto riesgo). En diabetes tipo 2 y en pacientes con síndrome metabólico se debe reducir el peso y aumentar la actividad física y en su caso utilizar los fármacos indicados, para alcanzar los objetivos de índice de masa corporal (IMC) y de perímetro de cintura. El objetivo en diabéticos tipo 2 debe ser alcanzar un nivel de hemoglobina glucosilada (HbA1c) <7%. La amplia difusión de las guías y el desarrollo de los programas destinados a favorecer su implantación, identificando barreras y buscando soluciones, son objetivos prioritarios del CEIPC, como uno de los medios fundamentales para trasladar las recomendaciones establecidas a la práctica clínica diaria (AU)
We present the Spanish adaptation made by the CEIPC of the European Guidelines on Cardiovascular Disease Prevention (CVD) in Clinical Practice 2008. This guide recommends the SCORE model for risk evaluation. The aim is to prevent premature mortality and morbidity due to CVD through the management of its related risk factors in clinical practice. The guide focuses on primary prevention and emphasizes the role of the nurses and primary care medical doctors in promoting a healthy life style, based on increasing physical activity, change dietary habits, and non smoking. The therapeutic goal is to achieve a Blood Pressure < 140/90 mmHg, but among patients with diabetes, chronic kidney disease, or definite CVD, the objective is <130/80 mmHg. Serum cholesterol should be < 200 mg/dl and cLDL<130 mg/dl, although among patients with CVD or diabetes, the objective is <100 mg/dl (80 mg/dl if feasible in very high-risk patients). Patients with type 2 diabetes and those with metabolic syndrome must lose weight and increase their physical activity, and drugs must be administered whenever applicable, to reach body mass index (BMI) guided and waist circumference objectives. In diabetic type 2 patients, the objective is glycated haemoglobin <7%. Allowing people to know the guides and developing implementation programs, identifying barriers and seeking solutions for them, are priorities for the CEIPC in order to transfer the recommendations established into the daily clinical practice (AU)
Asunto(s)
Humanos , Enfermedades Cardiovasculares/prevención & control , Medicina Clínica/normas , Diabetes Mellitus Tipo 2/prevención & control , Inhibidores de Agregación Plaquetaria/uso terapéutico , Biomarcadores , Presión Sanguínea , Índice de Masa Corporal , Enfermedades Cardiovasculares/mortalidad , Enfermedades Cardiovasculares/fisiopatología , Enfermedades Cardiovasculares/terapia , Colesterol/sangre , Ensayos Clínicos como Asunto , Estilo de Vida , Pautas de la Práctica en Medicina , Factores de Riesgo , EspañaRESUMEN
Presentamos la adaptación española realizada por el Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC) de la Guía Europea de Prevención de las Enfermedades Cardiovasculares 2008. Esta guía recomienda el modelo SCORE de riesgo bajo para valorar el riesgo cardiovascular. El objetivo es prevenir la mortalidad y la morbilidad debidas a las enfermedades cardiovasculares (ECV) mediante el tratamiento de sus factores de riesgo en la práctica clínica. La guía hace énfasis en la prevención primaria y en el papel del médico y el personal de enfermería de atención primaria en la promoción de un estilo de vida cardiosaludable, basado en el incremento de los grados de actividad física, la adopción de una alimentación saludable y, en los fumadores, el abandono del tabaco. La meta terapéutica para la presión arterial es en general < 140/90 mmHg; pero en pacientes con diabetes mellitus, enfermedad renal crónica o ECV el objetivo es 130/80 mmHg. El colesterol debe mantenerse por debajo de 200 mg/dl (colesterol unido a lipoproteínas de baja densidad [cLDL] < 130 mg/dl); en los pacientes con ECV o diabetes mellitus el objetivo es cLDL < 100 mg/dl (80 mg/dl si factible en individuos de riesgo muy alto). En pacientes con diabetes mellitus tipo 2 y en pacientes con síndrome metabólico se debe reducir el peso y aumentar la actividad física y, en su caso, utilizar los fármacos indicados, para alcanzar los objetivos del índice de masa corporal y de perímetro de cintura. El objetivo en pacientes con diabetes mellitus tipo 2 debe ser alcanzar una hemoglobina glucosilada < 7%. La amplia difusión de las guías y el desarrollo de los programas destinados a favorecer su implantación, en los que se identifiquen barreras y se busquen soluciones, son objetivos prioritarios del CEIPC, como uno de los medios fundamentales para trasladar las recomendaciones establecidas a la práctica clínica diaria(AU)
The present CEIPC Spanish adaptation of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice 2008. This guide recommends the SCORE model for risk evaluation. The aim is to prevent premature mortality and morbidity due to CVD by means of dealing with its related risk factors in clinical practice. The guide focuses on primary prevention and emphasizes the role of the nurses and primary care doctors in promoting a healthy life style, based on increasing physical activity, changing dietary habits, and not smoking. The therapeutic goal is to achieve a Blood Pressure < 140/90 mmHg, but in patients with diabetes, chronic kidney disease, or definite CVD, the objective is < 130/80 mmHg. Serum cholesterol should be < 200 mg/dl and cLDL < 130 mg/dl, although in patients with CVD or diabetes, the objective is < 100 mg/dl (80 mg/dl if feasible in very high-risk patients). Patients with type 2 diabetes and those with metabolic syndrome must lose weight and increase their physical activity, and drugs must be administered whenever applicable, with the objective guided by body mass index and waist circumference. In diabetic type 2 patients, the objective is glycated haemoglobin < 7%. Allowing people to know the guides and developing implementation programs, identifying barriers and seeking solutions for them, are priorities for the CEIPC in order to put the recommendations into practice(AU)
Asunto(s)
Humanos , Enfermedades Cardiovasculares/prevención & control , Pautas de la Práctica en Medicina/normas , Factores de Riesgo , Antihipertensivos/uso terapéutico , Hipertensión/complicaciones , Ajuste de Riesgo , Diabetes Mellitus/epidemiología , Insuficiencia Renal/epidemiologíaRESUMEN
The present CEIPC Spanish adaptation of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice 2008. This guide recommends the SCORE model for risk evaluation. The aim is to prevent premature mortality and morbidity due to CVD by means of dealing with its related risk factors in clinical practice. The guide focuses on primary prevention and emphasizes the role of the nurses and primary care doctors in promoting a healthy life style, based on increasing physical activity, changing dietary habits, and not smoking. The therapeutic goal is to achieve a Blood Pressure < 140/90 mmHg, but in patients with diabetes, chronic kidney disease, or definite CVD, the objective is < 130/80 mmHg. Serum cholesterol should be < 200 mg/dl and cLDL < 130 mg/dl, although in patients with CVD or diabetes, the objective is < 100 mg/dl (80 mg/dl if feasible in very high-risk patients). Patients with type 2 diabetes and those with metabolic syndrome must lose weight and increase their physical activity, and drugs must be administered whenever applicable, with the objective guided by body mass index and waist circumference. In diabetic type 2 patients, the objective is glycated haemoglobin < 7%. Allowing people to know the guides and developing implementation programs, identifying barriers and seeking solutions for them, are priorities for the CEIPC in order to put the recommendations into practice.
Asunto(s)
Enfermedades Cardiovasculares/prevención & control , Conducta , Enfermedades Cardiovasculares/sangre , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/etiología , Enfermedades Cardiovasculares/psicología , Enfermedades Cardiovasculares/terapia , Humanos , Hipertensión/complicaciones , Hipertensión/terapia , Factores de Riesgo , Factores Socioeconómicos , EspañaAsunto(s)
Humanos , Enfermedades Cardiovasculares/prevención & control , Guías como Asunto , Factores de Riesgo , Predisposición Genética a la Enfermedad , Hiperlipidemias/complicaciones , Insuficiencia Renal/complicaciones , Anticoagulantes/uso terapéutico , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Bloqueadores de los Canales de Calcio/uso terapéutico , Diuréticos/uso terapéutico , Antihipertensivos/uso terapéuticoRESUMEN
No disponible
No disponible
Asunto(s)
Humanos , Enfermedades Cardiovasculares/prevención & control , Ajuste de Riesgo/métodos , Complicaciones de la Diabetes/prevención & control , Factores de Riesgo , Relaciones Médico-Paciente , Fumar/efectos adversos , Sobrepeso/prevención & control , Obesidad/prevención & control , Hipertensión/prevención & control , Estilo de Vida , Lípidos/sangre , Diabetes Mellitus/prevención & control , Síndrome Metabólico/prevención & controlAsunto(s)
Humanos , Masculino , Femenino , Enfermedades Cardiovasculares/prevención & control , Factores de Riesgo , EspañaRESUMEN
No disponible
No disponible
Asunto(s)
Femenino , Humanos , Masculino , Anomalías Cardiovasculares/metabolismo , Diabetes Mellitus/sangre , Fumar/terapia , Sociedades Científicas/clasificación , Placa Aterosclerótica/complicaciones , Comité de Profesionales/ética , Comité de Profesionales/legislación & jurisprudencia , Farmacología/ética , Farmacología/métodos , Anomalías Cardiovasculares/patología , Diabetes Mellitus/patología , Diabetes Mellitus/prevención & control , Fumar/genética , Sociedades Científicas/economía , Placa Aterosclerótica/metabolismo , Placa Aterosclerótica/patología , Comité de Profesionales/organización & administración , Comité de ProfesionalesRESUMEN
Esta guía se centra en la prevención de la enfermedad cardiovascular en su conjunto, recomienda el modelo SCORE para valorar el riesgo y prioriza la atención a los pacientes y sujetos de alto riesgo. Los pacientes de alto riesgo deben incrementar su actividad física, elegir dietas cardiosaludables y los fumadores abandonar el tabaco. La decisión de iniciar el tratamiento farmacológico dependerá del riesgo cardiovascular y de posibles lesiones de órganos diana. Se incluye un anexo con recomendaciones dietéticas adaptadas a nuestro entorno y criterios de derivación o consulta con el especialista en hipertensión y dislipidemia
This guideline is focused on cardiovascular disease prevention as a whole. It recommends the SCORE model to assess risk and makes attention to high risk patients and subjects a priority. High risk patients should increase their physical activity, chose cardio-healthy diets, and those who smoke should break the habit. The decision to initiate drug treatment will depend on the cardiovascular risk and possible lesions of the target organs. An annex is included with dietary recommendation adapted to our setting and referral criteria or consultation with specialist in hypertension and dyslipidemia is included
Asunto(s)
Humanos , Enfermedades Cardiovasculares/prevención & control , Comité de Profesionales , Traducciones , Factores de Riesgo , EspañaRESUMEN
No disponible
Asunto(s)
Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/prevención & control , Enfermedad Cardiopulmonar/epidemiología , Enfermedad Cardiopulmonar/prevención & control , Cardiomiopatías/epidemiología , Cardiomiopatías/prevención & control , España/epidemiología , Factores de Riesgo , Lipoproteínas/análisis , Hiperlipidemias/prevención & controlRESUMEN
No disponible
Asunto(s)
Humanos , Enfermedades Cardiovasculares/prevención & control , Prevención Primaria/normas , Factores de Riesgo , Hipertensión/prevención & control , Aterosclerosis/prevención & controlRESUMEN
No disponible
Asunto(s)
Persona de Mediana Edad , Femenino , Humanos , Articulación de la Cadera , Factores de Tiempo , Tuberculosis Osteoarticular , DolorRESUMEN
No disponible
Asunto(s)
Persona de Mediana Edad , Anciano , Masculino , Femenino , Humanos , Terminología , Rombencéfalo , Tomografía Computarizada de Emisión de Fotón Único , Retención Urinaria , Amnesia , Imagen por Resonancia Magnética , Listeria monocytogenes , Listeriosis , TelencéfaloRESUMEN
BACKGROUND: Several epidemiological studies have demonstrated the beneficial effect of red wine intake in reducing total and cardiovascular mortality. This effect has been attributed in part to its antioxidant properties. Because the monocytes/macrophages and the nuclear transcription factor kappaB (NF-kappaB) are implicated in the pathogenesis of atherosclerotic lesions, we examined the effect of red wine intake on the activation of NF-kappaB in peripheral blood mononuclear cells. METHODS AND RESULTS: Sixteen healthy volunteers were studied 3 times each: after a moderate dose, a low dose, and no wine with a fat-enriched breakfast. Lipid profile and NF-kappaB activation (electrophoretic mobility shift assay) were examined in blood samples taken before and 3, 6, and 9 hours after wine intake. In addition, mononuclear cells were incubated with VLDL in the presence of some antioxidants (quercetin and alpha-tocopherol succinate) contained in red wine to study their effects on NF-kappaB activation. Subjects receiving a fat-enriched breakfast had increased NF-kappaB activation in peripheral blood mononuclear cells coinciding with the augmentation in total triglycerides and chylomicrons. Red wine intake prevented NF-kappaB activity even though it induced a certain increase in serum lipids, particularly VLDL, that did not increase after the fat ingestion alone. However, another form of alcohol intake (vodka) did not modify the NF-kappaB activation provided by postprandial lipemia. In cultured mononuclear cells, isolated human VLDL caused NF-kappaB activation in a time-dependent manner that did not occur in the presence of the red wine antioxidants quercetin and alpha-tocopherol. CONCLUSIONS: Our results provide a new potential mechanism to explain the beneficial effects of red wine intake in the reduction of cardiovascular mortality.